Effects of three different fibrates on intrahepatic cholestasis experimentally induced in rats

PPAR Research

Volumn , Issue , 2013, Pages

  El Sisi, Alaa ^a   Hegazy, Sahar ^a   El Khateeb, Eman ^a  

^a Tanta University   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BEZAFIBRATE; FENOFIBRATE; GEMFIBROZIL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; URSODEOXYCHOLIC ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE ACID SYNTHESIS; BILE FLOW; CHOLESTASIS; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DRUG MECHANISM; INTRAHEPATIC CHOLESTASIS; MALE; NONHUMAN; RAT;

EID: 84884254027     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2013/781348     Document Type: Article

References (55)

1. Trauner M., Boyer J. L., Bile salt transporters: molecular characterization, function, and regulation. Physiological Reviews 2003 83 2 633 671 2-s2.0-0037379362
2. Zollner G., Trauner M., Nuclear receptors as therapeutic targets in cholestatic liver diseases. British Journal of Pharmacology 2009 156 1 7 27 2-s2.0-65549145901 10.1111/j.1476-5381.2008.00030.x
3. Sturm E., Wagner M., Trauner M., Nuclear receptor ligands in therapy of cholestatic liver disease. Frontiers in Bioscience 2009 14 11 4299 4325 2-s2.0-63849111791 10.2741/3529
4. Torra I. P., Claudel T., Duval C., Kosykh V., Fruchart J.-C., Staels B., Bile acids induce the expression of the human peroxisome proliferator-activated receptor α gene via activation of the farnesoid X receptor. Molecular Endocrinology 2003 17 2 259 272 2-s2.0-0037315190 10.1210/me.2002-0120
5. Simon F. R., Fortune J., Iwahashi M., Gartung C., Wolkoff A., Sutherland E., Ethinyl estradiol cholestasis involves alterations in expression of liver sinusoidal transporters. The American Journal of Physiology 1996 271 6 G1043 G1052 2-s2.0-0030470648
6. Jansen P. L. M., Muumller M., Sturm E., Genes and cholestasis. Hepatology 2001 34 6 1067 1074 2-s2.0-0035183471 10.1053/jhep.2001.29625
7. Ros E., Small D. M., Carey M. C., Effects of chlorpromazine hydrochloride on bile salt synthesis, bile formation and biliary lipid secretion in the Rhesus monkey: a model for chlorpromazine-induced cholestasis. European Journal of Clinical Investigation 1979 9 1 29 41 2-s2.0-0018622372
8. Zimetbaum P., Frishman W. H., Kahn S., Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins. Journal of Clinical Pharmacology 1991 31 1 25 37 2-s2.0-0026062425
9. Gonzalez F. J., Peters J. M., Cattley R. C., Mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activated receptor. Journal of the National Cancer Institute 1998 90 22 1702 1709 2-s2.0-0032545018
10. Post S. M., Duez H., Gervois P. P., Staels B., Kuipers F., Princen H. M. G., Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor- α -mediated downregulation of cholesterol 7 α -hydroxylase and sterol 27-hydroxylase expression. Arteriosclerosis, Thrombosis, and Vascular Biology 2001 21 11 1840 1845 2-s2.0-0035570381
11. Chianale J., Vollrath V., Wielandt A. M., Amigo L., Rigotti A., Nervi F., Gonzalez S., Andrade L., Pizarro M., Accatino L., Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse. Biochemical Journal 1996 314 3 781 786 2-s2.0-0029922002
12. James N. H., Soames A. R., Roberts R. A., Suppression of hepatocyte apoptosis and induction of DNA synthesis by the rat and mouse hepatocarcinogen diethylhexylphlathate (DEHP) and the mouse hepatocarcinogen 1,4-dichlorobenzene (DCB). Archives of Toxicology 1998 72 12 784 790 2-s2.0-0032435561 10.1007/s002040050574
13. Reitman S., Frankel S., A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. American Journal of Clinical Pathology 1957 28 1 56 63 2-s2.0-66349129125
14. Walters M. I., Gerarde H. W., An ultramicromethod for the determination of conjugated and total bilirubin in serum or plasma. Microchemical Journal 1970 15 2 231 243 2-s2.0-49849114745
15. Yoshioka T., Kawada K., Shimada T., Mori M., Lipid peroxidation in maternal and cord blood and protective mechanism against activated-oxygen toxicity in the blood. American Journal of Obstetrics and Gynecology 1979 135 3 372 376 2-s2.0-0018318662
16. Said S. A., El-Agamy D. S., Effects of curcumin, resveratrol and ursodeoxycholic acid on ethinylestradiol and chlorpromazine-induced intrahepatic cholestasis in rats. Pharmacologyonline 2009 3 91 100 2-s2.0-74549167326
17. Vore M., Meers R. G., Harrison S. D., Bull R. J., Mechanisms of cholestasis. Hepatotoxicology 1991 Boca Raton Fla, USA CRC Press 525 568
18. Farrell G., Farrell G. C., Drug-induced cholestasis. Drug-Induced Liver Disease 1994 Edinburgh, UK Churchill Livingstone 319 370
19. Berr F., Simon F. R., Reichen J., Ethynylestradiol impairs bile salt uptake and Na-K pump function of rat hepatocytes. The American Journal of Physiology 1984 10 4 G437 G443 2-s2.0-0021688104
20. Keeffe E. B., Blankenship N. M., Scharschmidt B. F., Alteration of rat liver plasma membrane fluidity and ATPase activity by chlorpromazine hydrochloride and its metabolites. Gastroenterology 1980 79 2 222 231 2-s2.0-0018973009
21. Lele R., Lele V., Feinendegen L., Shreeve W., Eckelman W., Bahk Y.-W., Wagner H. Jr., Functional genomics and the liver. Molecular Nuclear Medicine 2003 Berlin, Germany Springer 527 562
22. Toler S. M., Oxidative stress plays an important role in the pathogenesis of drug-induced retinopathy. Experimental Biology and Medicine 2004 229 7 607 615 2-s2.0-3042729721
23. Hussein M. A., Abdel-Gawad S. M., Protective effect of Jasonia montana against ethinylestradiol-induced cholestasis in rats. Saudi Pharmaceutical Journal 2010 18 1 27 33 2-s2.0-75349092527 10.1016/j.jsps.2009.12.002
24. Obata T., Intrahepatic cholestasis and hyperbilirubinemia in ethynyl estradiol and chlorpromazine-treated rats. Gastroenterologia Japonica 1983 18 6 538 548 2-s2.0-0021071838
25. Sulaiman A. A., Al-Shawi N. N., Jwaied A. H., Mahmood D. M., Hussain S. A., Protective effect of melatonin against chlorpromazine-induced liver disease in rats. Saudi Medical Journal 2006 27 10 1477 1482 2-s2.0-36048972557
26. Cindoruk M., Kerem M., Karakan T., Salman B., Akin O., Alper M., Erdem O., Ünal S., Peroxisome proliferators-activated alpha agonist treatment ameliorates hepatic damage in rats with obstructive jaundice: an experimental study. BMC Gastroenterology 2007 7, article 44 2-s2.0-38849137817 10.1186/1471-230X-7-44
27. El-Azim T. A., Mahmoud A. H., Role of pravastatin and fenofibrate in protection against oxidative stress after extrahepatic biliary obstruction in rats. Bulletin Alexandria Faculty of Medicine 2006 42 2 533 534
28. Leuenberger N., Pradervand S., Wahli W., Sumoylated PPAR α mediates sex-specific gene repression and protects the liver from estrogen-induced toxicity in mice. Journal of Clinical Investigation 2009 119 10 3138 3148 2-s2.0-70349659645 10.1172/JCI39019
29. Nishioka T., Hyogo H., Numata Y., Yamaguchi A., Kobuke T., Komichi D., Nonaka M., Inoue M., Nabeshima Y., Ogi M., Iwamoto K., Ishitobi T., Ajima T., Chayama K., Tazuma S., A nuclear receptor-mediated choleretic action of fibrates is associated with enhanced canalicular membrane fluidity and transporter activity mediating bile acid-independent bile secretion. Journal of Atherosclerosis and Thrombosis 2005 12 4 211 217 2-s2.0-33644699708
30. Kobayashi A., Suzuki Y., Kuno H., Sugai S., Sakakibara H., Shimoi K., Effects of fenofibrate on plasma and hepatic transaminase activities and hepatic transaminase gene expression in rats. Journal of Toxicological Sciences 2009 34 4 377 387 2-s2.0-68549106059 10.2131/jts.34.377
31. Toyama T., Nakamura H., Harano Y., Yamauchi N., Morita A., Kirishima T., Minami M., Itoh Y., Okanoue T., PPAR α ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats. Biochemical and Biophysical Research Communications 2004 324 2 697 704 2-s2.0-5144224821 10.1016/j.bbrc.2004.09.110
32. Aviram M., Rosenblat M., Bisgaier C. L., Newton R. S., Primo-Parmo S. L., La Du B. N., Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions: a possible peroxidative role for paraoxonase. Journal of Clinical Investigation 1998 101 8 1581 1590 2-s2.0-0032522985
33. Chaput E., Maubrou-Sanchez D., Bellamy F. D., Edgar A. D., Fenofibrate protects lipoproteins from lipid peroxidation: synergistic interaction with α -tocopherol. Lipids 1999 34 5 497 502 2-s2.0-0033054105 10.1007/s11745-999-0390-8
34. Xu X., Otsuki M., Saito H., Sumitani S., Yamamoto H., Asanuma N., Kouhara H., Kasayama S., PPAR α and GR differentially down-regulate the expression of nuclear factor- B-responsive genes in vascular endothelial cells. Endocrinology 2001 142 8 3332 3339 2-s2.0-0034742712 10.1210/en.142.8.3332
35. Guéraud F., Alary J., Costet P., Debrauwer L., Dolo L., Pineau T., Paris A., In vivo involvement of cytochrome P450 4A family in the oxidative metabolism of the lipid peroxidation product trans-4-hydroxy-2-nonenal, using PPAR α -deficient mice. Journal of Lipid Research 1999 40 1 152 159 2-s2.0-0345059227
36. Kleemann R., Verschuren L., De Rooij B.-J., Lindeman J., De Maat M. M., Szalai A. J., Princen H. M. G., Kooistra T., Evidence for anti-inflammatory activity of statins and PPAR α activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 2004 103 11 4188 4194 2-s2.0-2542465868 10.1182/blood-2003-11-3791
37. Kanda T., Yokosuka O., Imazeki F., Saisho H., Bezafibrate treatment: a new medical approach for PBC patients? Journal of Gastroenterology 2003 38 6 573 578 2-s2.0-0037821923
38. Nakai S., Masaki T., Kurokohchi K., Deguchi A., Nishioka M., Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study. The American Journal of Gastroenterology 2000 95 1 326 327 2-s2.0-0033989267 10.1016/S0002-9270(99)00726-1
39. Yano K., Kato H., Morita S., Takahara O., Ishibashi H., Furukawa R., Is bezafibrate histologically effective for primary biliary cirrhosis? The American Journal of Gastroenterology 2002 97 4 1075 1077 2-s2.0-0036117828 10.1016/S0002-9270(02)04001-7
40. Kurihara T., Niimi A., Maeda A., Shigemoto M., Yamashita K., Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid. The American Journal of Gastroenterology 2000 95 10 2990 2992 2-s2.0-0033792659 10.1016/S0002-9270(00)02013-X
41. Kurihara T., Maeda A., Shigemoto M., Yamashita K., Hashimoto E., Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy. The American Journal of Gastroenterology 2002 97 1 212 214 2-s2.0-0036143517 10.1016/S0002-9270(01)03975-2
42. Ohmoto K., Mitsui Y., Yamamoto S., Effect of bezafibrate in primary biliary cirrhosis: a pilot study. Liver 2001 21 3 223 224 2-s2.0-0034962007 10.1034/j.1600-0676.2001.021003223.x
43. Jonker J. W., Liddle C., Downes M., FXR and PXR: potential therapeutic targets in cholestasis. Journal of Steroid Biochemistry and Molecular Biology 2011 2-s2.0-79960892872 10.1016/j.jsbmb.2011.06.012
44. Esposito E., Rinaldi B., Mazzon E., Donniacuo M., Impellizzeri D., Paterniti I., Capuano A., Bramanti P., Cuzzocrea S., Anti-inflammatory effect of simvastatin in an experimental model of spinal cord trauma: involvement of PPAR-alpha. Journal of Neuroinflammation 2012 81 2-s2.0-84860209867 10.1186/1742-2094-9-81
45. Peters J. M., Aoyama T., Burns A. M., Gonzalez F. J., Bezafibrate is a dual ligand for PPAR α and PPAR β: studies using null mice. Biochimica et Biophysica Acta 2003 1632 1-3 80 89 2-s2.0-0038694566 10.1016/S1388-1981(03)00065-9
46. Iwasaki S., Akisawa N., Saibara T., Onishi S., Fibrate for treatment of primary biliary cirrhosis. Hepatology Research 2007 37 3 S515 S517 2-s2.0-35348900226 10.1111/j.1872-034X.2007.00232.x
47. Ghose R., Mulder J., von Furstenberg R. J., Thevananther S., Kuipers F., Karpen S. J., Rosiglitazone attenuates suppression of RXR α -dependent gene expression in inflamed liver. Journal of Hepatology 2007 46 1 115 123 2-s2.0-34547108415 10.1016/j.jhep.2006.09.008
48. Scatena R., Bottoni P., Martorana G. E., Vincenzoni F., Botta G., Pastore P., Giardina B., Mitochondria, ciglitazone and liver: a neglected interaction in biochemical pharmacology. European Journal of Pharmacology 2007 567 1-2 50 58 2-s2.0-34249055222 10.1016/j.ejphar.2007.04.017
49. Zoete V., Grosdidier A., Michielin O., Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochimica et Biophysica Acta 2007 1771 8 915 925 2-s2.0-34547661571 10.1016/j.bbalip.2007.01.007
50. Nash D. T., Hyperlipoproteinemia, atherosclerosis and gemfibrozil. Angiology 1982 33 9 594 602 2-s2.0-0020415444
51. de Salcedo I., Gorringe A. L., Silva J. L., Santos J. A., Gemfibrozil in a group of diabetics. Proceedings of the Royal Society of Medicine 1976 69 supplement 2 64 70 2-s2.0-0017274040
52. Miller-Blair D., White R., Greenspan A., Acute gout involving the acromioclavicular joint following treatment with gemfibrozil. The Journal of Rheumatology 1992 19 1 166 168 2-s2.0-0026503841
53. Dellavalle R. P., Nicholas M. K., Schilling L. M., Melanoma chemoprevention: a role for statins or fibrates? American Journal of Therapeutics 2003 10 3 203 210 2-s2.0-0141765782
54. Dasgupta S., Roy A., Jana M., Hartley D. M., Pahan K., Gemfibrozil ameliorates relapsing-remitting experimental autoimmune encephalomyelitis independent of peroxisome proliferator-activated receptor- α Molecular Pharmacology 2007 72 4 934 946 2-s2.0-34748917549 10.1124/mol.106.033787
55. Roy A., Pahan K., Gemfibrozil, stretching arms beyond lipid lowering. Immunopharmacology and Immunotoxicology 2009 31 3 339 351 2-s2.0-70350671530 10.1080/08923970902785253